At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 194 enrolled
Drug / intervention
QVA149 +1 moredrug
Likely dose
QVA149 50 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MOVE - A Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
In Brief
A Phase 3 clinical trial evaluating QVA149 and Placebo for Chronic Obstructive Pulmonary Disease. Completed, enrolled 194 participants across 30 sites.
Detailed Summary
This study is designed to assess the effect of QVA149 (110/50 ug q.d.) versus placebo on pulmonary function and average physical activity levels in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartApr 2014
Primary CompletionFeb 2015
TodayJul 2026
First PostedNov 27, 2013
Enrollment StartApr 1, 2014
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 12.6 years ago
Interventions
QVA149drug
QVA149 (110/50 µg) once a day via Breezhaler® device
Placebodrug
Placebo once a day via Breezhaler® device